European Opportunities Loom For Value Added Medicines
But Sales Still Lag US, With EU Legislative Review Set To Address Sector’s Need For Reform
Upcoming opportunities facilitated by the EU’s pharma legislation review were highlighted at Medicines for Europe’s fifth annual value added medicines conference, held in Brussels in early November. However, enthusiasm was tempered with acknowledgements that the European sector current lags behind the US and needs further reform to attract investment.
You may also be interested in...
At Medicines for Europe’s fifth annual value added medicines conference, the association announced that Pharmanovia CEO James Burt would take over as chair of its value added medicines sector group from Viatris executive Arun Narayan.
Now that the first license for a drug has been obtained in partnership with the program, work will begin to ensure other companies that make the product adopt the new licensed indication.
Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.